Isolation of Human Melanoma Stem Cells Using ALDH as a Marker

Yuchun Luo1, Nicholas Nguyen1, Mayumi Fujita2

1 University of Colorado Denver, Aurora, Colorado, 2 Denver Veterans Affairs Medical Center, Denver, Colorado
Publication Name:  Current Protocols in Stem Cell Biology
Unit Number:  Unit 3.8
DOI:  10.1002/9780470151808.sc0308s26
Online Posting Date:  September, 2013
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

ABSTRACT

This unit describes a protocol for establishing a patient‐derived tumor xenograft model (PDTX model) of human melanoma and isolating human melanoma stem cells from human melanoma specimens using aldehyde dehydrogenase (ALDH) as a marker. One major limitation of analyzing a small fraction of cancer stem cells from patient tumor samples is that substantial quantities of fresh tumor tissues are not available. To overcome this challenge, we have established a PDTX model of human melanoma. In this model, human tumor tissues obtained from melanoma patients are dissected into small pieces and subsequently implanted into immunocompromised mice. The PDTX tumors retain fundamental genotypic and phenotypic features of the original tumors and are suitable for further biological analyses. Using the PDTX model, we have analyzed ALDH‐labeled human melanoma stem cells. This unit will describe how to establish a PDTX model using human tumor samples. We will also describe how to isolate and analyze ALDH‐labeled human melanoma stem cells using this model. Curr. Protoc. Stem Cell Biol. 26:3.8.1‐3.8.10. © 2013 by John Wiley & Sons, Inc.

Keywords: melanoma; patient‐derived tumor xenograft; cancer stem cell; aldehyde dehydrogenase

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Basic Protocol 1: Establishing a PDTX Model Using Human Melanoma Tumor Samples
  • Basic Protocol 2: Analysis of ALDH‐Labeled Human Melanoma Stem Cells
  • Reagents and Solutions
  • Commentary
  • Literature Cited
  • Figures
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1: Establishing a PDTX Model Using Human Melanoma Tumor Samples

  Materials
  • Human melanoma tumor specimens
  • RPMI‐1640 medium
  • Matrigel (BD Biosciences)
  • Nude mice (five‐ to six‐week‐old)
  • Isofluorane
  • Drysol (20% aluminum chloride in anhydrous ethyl alcohol)
  • 60‐cm2 sterile culture dishes
  • Sterile surgical blade, forceps, micro‐dissecting forceps, and scissors
  • 1.5‐ml microcentrifuge tubes
  • Anesthesia machine
  • Surgical clippers (9‐mm), clip applier and removal device (Roboz)
  • Cotton buds

Basic Protocol 2: Analysis of ALDH‐Labeled Human Melanoma Stem Cells

  Materials
  • Xenografted melanoma tissues or original human melanoma specimens
  • Tissue digestion solution (see recipe)
  • 1 × red blood cell lysis buffer (eBioscience)
  • Phosphate‐buffered saline (PBS; Cellgro, cat. no. 21‐040‐CV)
  • Trypan blue (Sigma‐Aldrich; also see unit 1.3)
  • Aldefluor kit (Stem Cell Technologies) containing:
    • Aldefluor buffer
    • DEAB
  • PE‐cy7‐labeled anti‐human CD45 (eBioscience)
  • PE‐cy7‐labeled anti‐human CD31 (eBioscience)
  • Allophycocyanin (APC)‐labeled anti‐mouse MHC Class I (H‐2Kd if BALB/c nude mice are used, eBioscience)
  • PE‐cy7‐labeled anti‐mouse CD45 (eBioscience)
  • PE‐cy7‐labeled anti‐rat IgG2b (eBioscience)
  • PE‐cy7‐labeled anti‐rat IgG2a (eBioscience)
  • APC‐labeled anti‐mouse IgG2a (eBioscience)
  • Ice
  • DAPI (Sigma‐Aldrich)
  • 100‐mm sterile petri dishes
  • Sterile surgical razor blades, forceps, and scissors
  • 15‐ml conical tubes
  • 10‐ml serological pipets
  • Water bath at 37°CVortex mixer
  • Centrifuge
  • 40‐ and 70‐µm cell strainers
  • Hemacytometer
  • MoFlo machine (DakoCytomation) to sort cells
  • Summit (DakoCytomation) software for data analysis
  • Additional reagents and equipment for trypan blue test of cell viability (unit 1.3)
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Alison, M.R., Guppy, N.J., Lim, S.M., and Nicholson, L.J. 2010. Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose? J. Pathol. 222:335‐344.
  Burger, P.E., Gupta, R., Xiong, X., Ontiveros, C.S., Salm, S.N., Moscatelli, D., and Wilson, E.L. 2009. High aldehyde dehydrogenase activity: A novel functional marker of murine prostate stem/progenitor cells. Stem Cells 27:2220‐2228.
  Chute, J.P., Muramoto, G.G., Whitesides, J., Colvin, M., Safi, R., Chao, N.J., and McDonnell, D.P. 2006. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 103:11707‐11712.
  Civenni, G., Walter, A., Kobert, N., Mihic‐Probst, D., Zipser, M., Belloni, B., Seifert, B., Moch, H., Dummer, R., van den Broek, M., and Sommer, L. 2011. Human CD271‐positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long‐term growth. Cancer Res. 71:3098‐3109.
  Daniel, V.C., Marchionni, L., Hierman, J.S., Rhodes, J.T., Devereux, W.L., Rudin, C.M., Yung, R., Parmigiani, G., Dorsch, M., Peacock, C.D., and Watkins, D.N. 2009. A primary xenograft model of small‐cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69:3364‐3373.
  Ginestier, C., Hur, M.H., Charafe‐Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M.S., and Dontu, G. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555‐567.
  Gray‐Schopfer, V., Wellbrock, C., and Marais, R. 2007. Melanoma biology and new targeted therapy. Nature 445:851‐857.
  Jordan, C.T., Guzman, M.L., and Noble, M. 2006. Cancer stem cells. N. Engl. J. Med. 355:1253‐1261.
  Kennedy, J.D., Pierce, C.W., and Lake, J.P. 1992. Extrathymic T cell maturation. Phenotypic analysis of T cell subsets in nude mice as a function of age. J. Immunol. 148:1620‐1629.
  Levi, B.P., Yilmaz, O.H., Duester, G., and Morrison, S.J. 2009. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood 113:1670‐1680.
  Luo, Y., Dallaglio, K., Chen, Y., Robinson, W.A., Robinson, S.E., McCarter, M.D., Wang, J., Gonzalez, R., Thompson, D.C., Norris, D.A., Roop, D.R., Vasiliou, V., and Fujita, M. 2012a. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30:2100‐2113.
  Luo, Y., Ellis, L.Z., Dallaglio, K., Takeda, M., Robinson, W.A., Robinson, S.E., Liu, W., Lewis, K.D., McCarter, M.D., Gonzalez, R., Norris, D.A., Roop, D.R., Spritz, R.A., Ahn, N.G., and Fujita, M. 2012b. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J. Invest. Dermatol. 132:2440‐2450.
  Magni, M., Shammah, S., Schiro, R., Mellado, W., Dalla‐Favera, R., and Gianni, A.M. 1996. Induction of cyclophosphamide‐resistance by aldehyde‐dehydrogenase gene transfer. Blood 87:1097‐1103.
  Prasmickaite, L., Engesaeter, B.O., Skrbo, N., Hellenes, T., Kristian, A., Oliver, N.K., Suo, Z., and Maelandsmo, G.M. 2010. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One 5:e10731.
  Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and Morrison, S.J. 2008. Efficient tumour formation by single human melanoma cells. Nature 456:593‐598.
  Quintana, E., Shackleton, M., Foster, H.R., Fullen, D.R., Sabel, M.S., Johnson, T.M., and Morrison, S.J. 2010. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510‐523.
  Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105‐111.
  Rubio‐Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio‐Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P.V., Kuramochi, H., Tanaka, K., Singh, S., Salimi‐Moosavi, H., Bouraoud, N., Amador, M.L., Altiok, S., Kulesza, P., Yeo, C., Messersmith, W., Eshleman, J., Hruban, R.H., Maitra, A., and Hidalgo, M. 2006. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12:4652‐4661.
  Santini, R., Vinci, M.C., Pandolfi, S., Penachioni, J.Y., Montagnani, V., Olivito, B., Gattai, R., Pimpinelli, N., Gerlini, G., Borgognoni, L., and Stecca, B. 2012. Hedgehog‐GLI signaling drives self‐renewal and tumorigenicity of human melanoma‐initiating cells. Stem Cells 30:1808‐1818.
  Sophos, N.A. and Vasiliou, V. 2003. Aldehyde dehydrogenase gene superfamily: The 2002 update. Chem. Biol. Interact. 143‐144:5‐22.
  Tentler, J.J., Tan, A.C., Weekes, C.D., Jimeno, A., Leong, S., Pitts, T.M., Arcaroli, J.J., Messersmith, W.A., and Eckhardt, S.G. 2012. Patient‐derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9:338‐350.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library